MedTrace Logo

A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries

NCT03037411 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 291

Last updated 2026-03-31

Study results available
· View outcomes & findings →

Summary

The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.

Conditions

  • Arterial Occlusive Diseases
  • Atherosclerosis
  • Vascular Diseases
  • Arteriosclerosis

Interventions

DEVICE

Peripheral stenting

stent implantation during the index procedure

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Carlo Setacci · Policlinico Le Scotte, Siena

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-13
Primary Completion
2022-03-24
Completion
2022-03-24

Countries

  • Austria
  • Belgium
  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03037411 on ClinicalTrials.gov